Correction to: 1-13C-propionate breath testing as a surrogate endpoint to assess efficacy of liver-directed therapies in methylmalonic acidemia (MMA) (Genetics in Medicine, (2021), 23, 8, (1522-1533), 10.1038/s41436-021-01143-8)

Irini Manoli; Alexandra R. Pass; Elizabeth A. Harrington; Jennifer L. Sloan; Jack Gagné; Samantha McCoy; Sarah L. Bell; Jacob D. Hattenbach; Brooks P. Leitner; Courtney J. Duckworth; Laura A. Fletcher; Thomas M. Cassimatis; Carolina I. Galarreta; Audrey Thurm; Joseph Snow; Carol Van Ryzin; Susan Ferry; Nicholas Ah Mew; Oleg A. Shchelochkov; Kong Y. Chen; Charles P. Venditti

ArticleOPEN ACCESS

Correction to: 1-13C-propionate breath testing as a surrogate endpoint to assess efficacy of liver-directed therapies in methylmalonic acidemia (MMA) (Genetics in Medicine, (2021), 23, 8, (1522-1533), 10.1038/s41436-021-01143-8)

Genetics in Medicine

DOI: 10.1038/s41436-021-01188-9

1Citations

3Readers

Get full text

Abstract

Due to a processing error, the online graphical abstract was not given The original article has been corrected.

Cite

CITATION STYLE

APA

Manoli, I., Pass, A. R., Harrington, E. A., Sloan, J. L., Gagné, J., McCoy, S., … Venditti, C. P. (2021, November 1). Correction to: 1-13C-propionate breath testing as a surrogate endpoint to assess efficacy of liver-directed therapies in methylmalonic acidemia (MMA) (Genetics in Medicine, (2021), 23, 8, (1522-1533), 10.1038/s41436-021-01143-8). Genetics in Medicine. Springer Nature. https://doi.org/10.1038/s41436-021-01188-9

Correction to: 1-13C-propionate breath testing as a surrogate endpoint to assess efficacy of liver-directed therapies in methylmalonic acidemia (MMA) (Genetics in Medicine, (2021), 23, 8, (1522-1533), 10.1038/s41436-021-01143-8)

Abstract

Cite

Register to see more suggestions